You are here: Industry Insights > Amgen

News List

Amgen, Allergan Submit BLA for Biosimilar Candidate americanpharmaceuticalreview
December 23, 2019
Amgen and Allergan announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab).
Amgen-UCB’s Evenity receives EC approval to treat osteoporosis pharmaceutical-technology
December 16, 2019
Amgen and UCB have received the European Commission (EC) approval for Evenity (romosozumab) to treat severe osteoporosis in postmenopausal women at high fracture risk.
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade drugs
December 11, 2019
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab) ...
Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia worldpharmanews
September 26, 2019
Amgen announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.
Amgen's Aimovig, under fire from Lilly, loses grip on next-gen migraine share fiercepharma
September 08, 2019
Amgen had a head start with its first-to-market CGRP launch Aimovig, but its rivals are giving the company some fierce competition.
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 americanpharmaceuticalreview
September 03, 2019
Regeneron Pharmaceuticals and Sanofi announced the U.S. District Court for the District of Delaware ruled in their favor and found as a matter of law that Amgen's asserted patent claims for antibodies targeting PCSK9 ...
Wham! Alexion investors sucker-punched as PTO takes up Amgen's Soliris patent challenge fiercepharma
September 02, 2019
Alexion Pharmaceuticals investors were celebrating last week when word on the street said Amgen might buy out the company, but a week later, their mood is much different.
Amgen to acquire Otezla® for $13.4 billion in cash worldpharmanews
August 27, 2019
Amgen announced today that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire...
Amgen Acquires Rights to Celgene’s Otezla contractpharma
August 27, 2019
Expands inflammation franchise with oral, non-biologic treatment for psoriasis and psoriatic arthritis.
Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab) worldpharmanews
August 23, 2019
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page